Diversa Corporation and Celera Genomics have announced the completion of the entire genome sequence of Streptomyces diversa.
The companies completed the sequencing under the collaborative agreement signed in December of 2000.
The availability of the genome sequence should enable faster discovery and development of novel molecules of pharmaceutical interest from Diversa’s PathwayLibraries.
Diversa‘s proprietary strain, Streptomyces diversa, belongs to an important group of microorganisms, the actinomycetes, that produce the majority of antibiotics used in human and veterinary medicine and agriculture, as well as immuno-suppressants, anti-parasitic agents, and herbicides.
The availability of the genome sequence, together with the application of technologies permitting the global analysis of gene expression at both the RNA and protein levels, and the extensive array of tools available for the genetic manipulation of this organism, will enable Diversa to fully utilize S. diversa for the production of novel compounds of pharmaceutical interest.
Diversa Corporation is a global leader in developing and applying proprietary technologies to discover and evolve novel genes and gene pathways from diverse environmental sources.
The Celera Genomics Group, headquartered in Rockville, MD, intends to be the definitive source of genomic and related medical information.